Last reviewed 2026-04-20 · How we verify

Assorted Licensed Hand Sanitizer Grape 01 (Licensed Influenza Vaccine 3)

Licensed Influenza Vaccine 3 is a marketed intranasal influenza vaccine developed by BioNTech SE. It targets influenza virus types A and B in individuals 6 years of age and older. The vaccine has generated $21.2B in revenue. It is a key product in BioNTech's portfolio. The company has conducted 72 trials and published 4 studies on the vaccine. BioNTech's expertise in mRNA technology has contributed to the vaccine's success.

At a glance

Approved indications

• Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older

Common side effects

• Irritability
• Pain
• Drowsiness
• Redness
• Swelling
• Loss of appetite
• Injection site pain (PAIN)
• Fever
• Fatigue (FATIGUE)
• Increase in limb circumference
• Headache (HEADACHE)
• Myalgia (MUSCLE PAIN)

Drug interactions

• Live vaccines
• Interferons
• Immunosuppressive drugs
• Corticosteroids
• Antiviral drugs
• Aspirin
• Warfarin
• Other anticoagulants

Key clinical trials

• A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
• A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
• A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (PHASE1)
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
• Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
• Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Assorted Licensed Hand Sanitizer Grape 01 CI brief — competitive landscape report
• Assorted Licensed Hand Sanitizer Grape 01 updates RSS · CI watch RSS
• BioNTech portfolio CI